Entheos Labs is developing psychedelic compounds to create therapeutic solutions for mental health conditions such as schizophrenia, Alzheimer's disease, and traumatic brain injury. The company utilizes advanced neuroscience research to address the urgent need for effective treatments in a mental health crisis exacerbated by the Covid-19 pandemic.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The current mental health crisis, exacerbated by events like the Covid-19 pandemic, demands more effective, faster-acting, and safer therapeutics for conditions like mood, anxiety, trauma-based, and substance use disorders. Existing treatments often fall short in providing rapid and enduring benefits across a wide range of indications.
Solution
Entheos Labs is developing psychedelic compounds to create breakthrough therapeutic solutions for various mental health conditions. The company harnesses the potential of psychedelics to address unmet medical needs by focusing on mood, anxiety, trauma-based, and substance use disorders. Their approach involves advanced neuroscience research to develop safe and effective therapeutic solutions.
Target Audience
The primary target audience includes individuals suffering from mood, anxiety, trauma-based, and substance use disorders, as well as healthcare systems seeking more effective mental health treatments.
Features
- Development of novel psychedelic compounds for mental health treatment.
- Focus on mood, anxiety, trauma-based, and substance use disorders.
- Utilizes advanced neuroscience research to identify and develop therapeutic solutions.